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Abstract
The transcription factor Foxp3 represents the most specific functional marker of CD4+ regulatory T cells (TRegs). However,
previous reports have described Foxp3 expression in other cell types including some subsets of macrophages, although
there are conflicting reports and Foxp3 expression in cells other than Treg is not well characterized. We performed detailed
investigations into Foxp3 expression in macrophages in the normal tissue and tumor settings. We detected Foxp3 protein in
macrophages infiltrating mouse renal cancer tumors injected subcutaneously or in the kidney. Expression was
demonstrated using flow cytometry and Western blot with two individual monoclonal antibodies. Further analyses
confirmed Foxp3 expression in macrophages by RT PCR, and studies using ribonucleic acid-sequencing (RNAseq)
demonstrated a previously unknown Foxp3 messenger (m)RNA transcript in tumor-associated macrophages. In addition,
depletion of Foxp3+ cells using diphtheria toxin in Foxp3DTR mice reduced the frequency of type-2 macrophages (M2) in
kidney tumors. Collectively, these results indicate that tumor-associated macrophages could express Foxp3.
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Introduction
The forkhead lineage-transcription factor Foxp3 was initially
characterized as a specific key intracellular marker of CD25+CD4+
T regulatory cells (TRegs) [1,2]. Its expression has since been
reported in more cell subsets including a minor subset of
CD8+CD25+ T cells [3] and some non-hematopoietic normal
epithelial cells, such as thymic stromal cells [4], breast epithelium
[5], bronchial and prostate epithelial cells [6] and tumor cells [7].
However, those observations remained controversial as some
studies argued that previous reports of Foxp3 expression in cell
types other than CD4+ T cells were not reproducible and were due
to staining artefacts [8].
Myeloid cells are important cells in the tumor microenviron-
ment, able to regulate immunity and promote tumor growth.
Among them, type-2 differentiated macrophages (M2) are strongly
immunosuppressive in different types of tumor microenvironment
[9].
In June 2011, an article was published in the Journal of
Experimental Medicine reporting the expression of Foxp3 in F4/
80hi/CD11bint macrophages with immunosuppressive potential
[10]. Subsequently, the paper was retracted on request of the
institute that published the work because other groups were unable
to detect Foxp3 in macrophages [11,12]. In these latter studies, the
authors were unable to detect Foxp3 in naive or activated
macrophages, but a detailed investigation in the tumor setting was
not performed. Nevertheless, Foxp3 expression in other cell types
remains highly controversial and is still fiercely debated. In the
present study we confirmed a lack of expression of Foxp3 in
normal macrophages, but we observed Foxp3 expression in
macrophages infiltrating mouse renal cell carcinoma tumors.
Using multiple assays, our observations indicate that Foxp3 can be
expressed in tumor-associated macrophages.
Materials and Methods
Cell Lines, mice and tumors
BALB/c wild-type (WT), SCID mice and Foxp3DTR mice were
bred and maintained at the Peter MacCallum Cancer Centre. All
mice were utilized following the Peter MacCallum Cancer Centre
Animal Experimentation Ethics Committee guidelines. The
BALB/c mice renal cell carcinoma cell lines Renca and Renca
Cherry Luciferase (Renca Ch+L+) were used and generated as
previously described [13]. Subcutaneous (SC) and intra-kidney
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(IK) orthotopic tumors were established as previously described
[13] by injection of 26105 Renca cells or Renca Ch+L+ cells.
Depletions in Foxp3DTR mice were performed using a single intra-
peritoneal (IP) injection of 0.5 mg diphtheria toxin (DT) (Sigma
Aldrich) at day 9 after tumor cell injection.
Ethics statement
This study was carried out in strict accordance with the
recommendations of the Victorian Bureau of Animal Welfare,
Department of Primary Industries, and the National Health and
Medical Research Council’s Australian code of practice for the
care and use of animals for scientific purposes. The protocol was
approved by the Peter MacCallum Cancer Centre Animal
Experimentation Ethics Committee under Permit numbers
E498. All efforts were made to minimize suffering.
Tumor processing, antibodies and FACS analysis
FACS analyses in IK or SC tumors were performed approx-
imately 14 days after tumor inoculation (D14) in wild type mice
and 4 days after DT injection, in the Foxp3DTR model. SC or IK
tumors, spleen and naı¨ve kidney were excised from mice and
dissociated. Bone marrow cells were collected using 26G syringe
and 2 washes of 2 ml of PBS through lower leg bones. Cells were
stained with anti-mouse CD45.2-FITC or APC-eF780 (clone 104),
CD11c-PE-Cy7 (clone N418), TCRb-PerCP-Cy5.5 (clone H57-
597), CD25-APC-eF780 (clone PC61.5), F4/80-PE-Cy7 (clone
BM8), CD4-APC-eF780 (clone RM4-5), CD11b-APC or APC-
eF780 (clone M1/70), CD19-AF647 (clone eBio1D3) (all from
eBioscience). The mouse anti-Foxp3 antibodies used for the
intracellular staining were PE coupled (clone NRRF-30) or APC-
coupled (FJK-16S), (all from eBioscience). Intracellular staining for
Foxp3 was performed according to manufacturer’s instructions.
Briefly, after two washes in PBS, the cell pellet was fixed using
100 ml of fixation buffer and incubated for 20 minutes, followed by
addition of 2 ml of PermWash buffer, centrifugation and a further
wash in PermWash. Cells were then resuspended in 50 ml of
PermWash and 50 ml of anti-Foxp3 antibody added and incubated
for 20 minutes. 2 ml of PermWash was then added followed by
centrifugation and a further wash in 2 ml of PBS. All incubations
were performed in the dark on ice. Cells were analyzed and sorted
on BD FACS CantoII and DIVA SORTER (BD Bioscience).
Western blot
Sorted cells were lysed in Radioimmunoprecipitation assay
buffer (RIPA) buffer (150 mM NaCl, 10 mM Tris-Cl, pH 7.4,
5 mM EDTA, 1% Triton X100, 0.1% SDS, 0.5% sodium
deoxycholate). Proteins (10 to 50 mg) were separated and
membranes were incubated overnight at 4uC with anti-mouse
Foxp3 purified antibodies and 1 h at room temperature with anti-
b actin antibody (clone AC-74, Sigma Aldrich). Immunoreactive
bands were visualized by enhanced chemiluminesence (Amer-
sham).
Foxp3 mRNA expression analysis
Total RNA from cells was extracted from cells using Qiagen
RNeasy kit (Qiagen) according to the manufacturer’s instructions.
For RT-PCR, the following primers were used on 1 ml of cDNA:
Foxp3 forward 59-AGACCCCTGTGCTCCAAGTG-39 and re-
verse 59- CAGACTCCATTT-GCCAGCAG-39 and HPRT
forward 59- GCTGGTGAAAAGGACCTCT-39 and reverse 59-
CACAGGACTAGAACACCTGC-39.
Paired-end RNA sequencing with read length of 51 bases was
performed on the selected RNA samples using Illumina
HiSeq2000. Total base reads after a quality trim exceeded
56109 per sample. Sequence alignment was performed using
Bowtie 0.12.8 [14] and TopHat v1.4.1 [15] against Mus musculus
reference genome MM9. Cufflinks 2.1.0 [16] was used to identify
transcripts that were present in the RNA samples and to estimate
abundances of the transcripts and genes in FPKM units
(Fragments Per Kilobase of transcript per Million mapped reads).
Mouse genome annotation from Ensembl release 67 was used to
guide Cufflinks for transcript assembly. The full data set is
available in the Gene Expression Omnibus (http://www.ncbi.nlm.
nih.gov/geo), accession number GSE56904.
Statistical Analysis
Results are expressed as the mean6 standard error of the mean
(SEM). Experiments were analyzed using a Mann-Whitney test,
and p,0.05 considered significant.
Results
Foxp3 protein detected in macrophages
In previous work, we demonstrated that IK tumors, highly
infiltrated with F4/80hi/CD11bin expressing macrophages (M2),
were more resistant to a combination agonist antibody immuno-
therapy in comparison to SC tumors [13]. To further characterize
the M2 macrophages infiltrating IK tumors in our tumor model,
we investigated the expression of several markers associated with
immunosuppression including Foxp3. We initially performed flow
cytometry with a routinely used anti-Foxp3 antibody, clone FJK-
16S (eBioscience, San Diego, CA), which recognizes an epitope
between amino-acids (AA) 75 and 125 of the Foxp3 protein
(Figure 1A). Our analysis revealed that M2 cells, gated on F4/
80hi/CD11bint, were mainly positive for Foxp3 expression in both
SC and IK Renca tumors compared to F4/80int/CD11bhi type-1
macrophages (M1) (Figure 1B, C). To confirm Foxp3 expression,
we also used another anti-Foxp3 antibody (clone NRRF-30 from
eBioscience), that recognizes a different epitope AA1 to AA75
(Figure 1A). To prevent contamination in the fluorescence-
activated cell sorting (FACS) coming from TReg cells, we initially
gated on CD45.2+/TCRneg cells. Flow cytometric analysis using
clone NRRF-30 demonstrated again that the majority of M2 and
some M1, infiltrating IK tumors, express Foxp3 (Figure 1D, E).
We next sought to confirm these results showing the expression
of Foxp3 in M2 macrophages by performing Western blots. The
anti-Foxp3 antibody clone FJK-16S detected a single band at the
expected Foxp3 protein size of 52 kDa in the positive control
CD4+ sorted cells from IK tumors and CD4+ Foxp3-GFP+ cells
from Foxp3DTR mice (Figure 1F). A single band was also
detected in the Western blot in the M2 cells sorted from IK
tumors but the size was heavier than expected, approximately
65 kDa (Figure 1F). This result was repeated in Western blots on
M2 cells, performed using the other antibody with a discrete
epitope, clone NRRF-30 (Figure 1G). Together, these results
suggest that M2 macrophages could potentially express Foxp3
protein. We hypothesize that the heavier size of the Foxp3 protein
in the M2 compared to CD4+ cells could be due to post-
translational modifications. Alternatively, it is possible that a
variant mRNA was responsible for the 65 KDa protein in
macrophages.
Foxp3 detection is specific for macrophages in tumor-
bearing mice
In order to assess whether Foxp3 expression was specific for
macrophages from Renca tumors, we performed flow cytometric
analysis on macrophages and other cell subsets from normal
Foxp3 Expression in Macrophages
PLOS ONE | www.plosone.org 2 September 2014 | Volume 9 | Issue 9 | e108670
Figure 1. Foxp3 protein detected in macrophages using two different Foxp3 antibody clones recognizing different epitopes. (A)
Schematic representation of Foxp3 protein with different known domains in Foxp3 protein: Zn f (Zinc finger), L Z (leucine zipper), FKH (Forkhead
domain), N and C (respectively N terminal and C terminal extremities of the protein) and the amino-acid epitopes 1 to 75 for anti-Foxp3 antibody
clone NRRF-30 and 75 to 125 for anti-Foxp3 antibody clone FJK16S (according to eBioscience datasheet). (B) Mice were inoculated at day 0 with
26105 Renca Ch+ L+ tumor cells intrakidney (IK) or subcutaneously (SC). Representative FACS analysis with gating strategy used for macrophages
(stained using anti-F4/80 and anti-CD11b antibodies) in IK tumors (left panel) and Foxp3 expression in type-2 (M2) and type-1 (M1) macrophages
from SC and IK tumors (right panels) at day 14. Black line represents FJK-16S clone for anti-Foxp3 antibody and grey line a Rat IgG2A isotype control.
(C) Quantitative data of percent positive cells (left panel) and mean of fluorescence (right panel) of Foxp3 expression in M2 and M1, analyzed on
represented gates (B, left panel) and using FJK-16S clone (one representative experiment of 4, n = 4 mice/group). (D) Representative FACS analysis
and (E) quantitative data of Foxp3 expression in M2 and M1 macrophages from renca Ch+ L+ IK tumors at day 14 using antibody clone NRRF-30 (one
representative experiment among 3, n = 4 mice/group). *P,0.05, **P,0.005, ***P,0.0005. (F) Western blot for Foxp3 using FJK-16S clone on M2,
CD4+ sorted from lysed IK tumors at day 14, and control CD4+ GFP2 and CD4+ GFP+ sorted cells from a naive Foxp3DTR mouse spleen (one
representative experiment of 3). (G) Western blot for Foxp3 using antibody clones FJK-16S and NRRF-30 on M2 sorted from IK tumors and total
splenocytes (spleno) (one representative experiment of 3). The ladders are represented in kilodalton (kDa).
doi:10.1371/journal.pone.0108670.g001
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kidney, bone marrow (BM) and spleen harvested from naı¨ve mice
and IK tumor-bearing mice. TRegs were stained as a positive
control, and we always detected Foxp3 expression in these cells
isolated from all organs, demonstrating that Foxp3 antibody
staining was effective in all conditions (Figure 2A, B first line).
We readily detected Foxp3 expression in macrophages (F4/80+/
CD11b+ cells) from IK tumors at lower level than TRegs. In
addition, low level Foxp3 staining was observed in macrophages
from BM or spleen in tumor-bearing mice (Figure 2B second
line). In a naı¨ve context, we did not detect Foxp3 expression in
macrophages from any organs (Figure 2A), supporting the idea
that Foxp3 expression was specifically associated with the tumor
context. Furthermore, we did not detect any Foxp3 expression in
other myeloid cells (F4/802/CD11b+ cells) or in dendritic cells
(DCs) or B cells from organs in naı¨ve or IK tumor-bearing mice
(Figure 2A, B). Finally, since antibodies vary in their capacity for
non-specific staining, we wanted to confirm our observations using
another isotype control antibody. We compared FACS staining
using the previous isotype control, clone eBr2a, and another
isotype control clone (clone R35-95, BD Bioscience) on TRegs
from naı¨ve spleen and myeloid cells from naı¨ve BM (Figure 2C).
Staining using both isotype control antibodies was similar and
negative compared to positive staining with a Foxp3-specific
antibody in TRegs and negative staining in myeloid cells. We
demonstrated here that significant Foxp3 expression was found
only in tumor infiltrating macrophages.
At this stage of the study, two hypotheses could explain the
unexpected expression of Foxp3 protein in macrophages. First,
translation of an intrinsic Foxp3 messenger RNA (mRNA) could
occur in macrophages, perhaps followed by post-translational
modification. Second, macrophages infiltrating tumors could
potentially internalize the protein from Foxp3 expressing cells
such as surrounding TRegs from the tumor microenvironment or
tumor cells themselves.
Foxp3 is expressed endogenously in M2 macrophages
To assess the hypothesis that M2 macrophages could endocy-
tose Foxp3 protein from TRegs we performed flow cytometric
staining for Foxp3 in M2 cells from IK tumors from wild type
(WT) or SCID mice, which lack TRegs. As a positive control,
Foxp3 positive staining was confirmed on TRegs from WT mice
(Figure 3A left panel). The lack of TRegs in SCID mice did not
impact on the macrophage (M2/M1) profile in IK tumor
(Figure 3A). We detected similar levels of Foxp3 expression in
M2 cells from WT and SCID mice suggesting an intrinsic
expression of the protein in the macrophages rather than
phagocytosis of Foxp3 from surrounding TRegs in the tumor
microenvironment (Figure 3A middle and right panels). This
result was confirmed by Western blot, where we could detect a
similar size (65 kDa) Foxp3 protein in IK-tumor infiltrating M2
from both WT and SCID mice (Figure 3B).
To investigate if Foxp3 protein was produced endogenously in
M2 macrophages following gene transcription, we used Foxp3DTR
transgenic mice in which the diphtheria toxin receptor (DTR) and
green fluorescence protein (GFP) are expressed under the control
of the Foxp3 promoter. In this model, Foxp3-expressing TRegs
are GFP+ and can be depleted using diphtheria toxin (DT) [17].
One dose of DT injected intraperitoneally (IP) in the mice at day 9
after IK tumor implantation was sufficient to deplete most of the
TRegs in the blood and tumor (Figure 3C, E upper panel).
GFP expression was not detected in macrophages from the blood
(F4/80+/CD11b+) or M2 cells from IK tumors (Figure 3D).
However, the depletion of Foxp3 positive cells in the tumor
following DT injection also reduced the M2 population (Fig-
ure 3D IK tumor and 3E) suggesting a Foxp3-dependent
depletion of M2 population. This implies that, despite the difficulty
in detecting GFP in macrophages, those cells might express the
DTR and be depleted following administration of DT.
Foxp3 messenger RNA was detected in macrophages
In order to further assess if Foxp3 protein was intrinsically
produced in macrophages, we analyzed the transcriptome of the
cells using a genome-wide technique. We performed RNA-
sequencing (RNAseq) analysis on RNA extracted from M1 and
M2 cells isolated from kidney tumors and splenic CD4+ T cells.
Cufflinks 2.1.0 analysis using mouse genome MM9 revealed three
Foxp3 mRNA variants in the CD4+ T cells expressed at a higher
level than the level of high confidence (Figure 4A), corresponding
to the three known isoforms of Foxp3 mRNA in mouse cells
(Foxp3, Mus musculus, NCBI Gene) (Figure 4B), but none of
these isoforms was significantly detected in M1 or M2 macro-
phages (Figure 4A, B). However a low but significant level (0.057
FKPM) of a fourth variant (var 4) was detected in M2 and M1
macrophages but not in CD4+ T cells (Figure 4A, B). Consid-
ering that all RNA transcripts detected to a FPKM level higher
than 0.046 are present with high confidence in the cells
(Figure 4A), we could consider that Foxp3 mRNA variant #4
was present in macrophages. mRNA variant #4 has not been
described previously. It appeared to be smaller than previous
Foxp3 mRNA transcripts (3527 bases) and the coding sequence
seems to be conserved on this variant#4 with an extra 23 bases on
the 59UTR compared to the variant #1 (Figure 4C).
To confirm the existence of Foxp3 mRNA in macrophages
indicated by RNAseq results, we performed highly sensitive RT-
PCR. We used Foxp3 primers to amplify within the coding
sequence conserved between the four Foxp3 mRNA variants
(Figure 4C). PCR products were detected at the expected size
when using complementary deoxyribonucleic acid (cDNA) gener-
ated from positive control TRegs and at a lower extent on some
M2 cells sorted from IK tumors (Figure 4D). This result confirms
the presence of a Foxp3 mRNA coding for the Foxp3 protein in
M2 macrophages. Also, we were able detect a very faint band for
Foxp3 mRNA in some macrophage cells sorted from BM from
IK-tumor bearing mice but not naı¨ve mice confirming our
previous FACS analysis (Figure 2A). We confirmed this result
with Western blot analysis (Figure 4E), suggesting the presence of
Foxp3-expressing macrophages in other organs in context of the
tumor being present. Finally, we detected Foxp3 mRNA in Renca
tumor cells from an in vivo IK solid tumor isolated using FACS
based on expression of the Cherry fluorochrome (Figure 4D).
However, this observation was not confirmed at a protein level
using Western blot and flow cytometry (Figure 4E, F).
Discussion
In the present study, we identified Foxp3, a transcription factor
usually expressed in TRegs, in kidney tumor-associated macro-
phages. We provide evidence of Foxp3 expression at the protein
level using antibody-based detection techniques. Two different
antibodies, available commercially, with non-overlapping epitopes
on the Foxp3 protein (clone FJK-16S AA75-AA125 and clone
NRRF-30 AA1-AA75), recognise Foxp3 in Renca tumor infiltrat-
ing macrophages, mainly in the M2 population. In addition, a
protein blast between sequence AA1 to AA125 of Foxp3 protein
and the entire UniProt database from multiple animal species
(NCBI Blast: Protein Sequence) did not identify any significant
homology between other proteins and AA1 to AA125 of the Foxp3
protein. Finally, Foxp3 protein was not observed in myeloid cells
Foxp3 Expression in Macrophages
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other than macrophages, supporting the idea of a specific Foxp3
protein detection in tumor-associated macrophages.
Surprisingly, we identified that the Foxp3 protein present in
macrophages, exhibited a molecular weight of approximately 65
KDa, higher than the 54 kDa normally expected. We hypothesise
that this apparent larger size of the Foxp3 protein may involve
some post-translational modifications. Indeed, some post-transla-
tional modifications such as ubiquitination or sumoylation, that
often occur on transcription factors [18,19], could potentially
explain the extra 10 to 15 kDa of Foxp3 in the macrophages.
The initial JEM retracted article described the expression of
Foxp3 in macrophages infiltrating various organs in a naive
context [20]. The controversy concerning expression of Foxp3 in
cells other than Treg continued in other studies, but the tumor
setting was minimally investigated [11,12]. In line with these two
latest studies, we did not detect Foxp3 in macrophages from naive
spleen, BM and kidney. However, when we investigate a Renca
kidney tumor setting, we detected Foxp3 expression in macro-
phages infiltrating the tumors.
Foxp3 expression following a M2-phagocytosis of the protein
expressed by the surrounding tumoral TRegs appears unlikely as
we still detected Foxp3 in M2 from SCID mice that lack TRegs.
Furthermore, M2 were depleted from the IK tumors in the
Foxp3DTR mouse model, implying that in those mice, Foxp3 and
DTR were expressed by M2. Nonetheless, we were not able to
detect any GFP expression in M2, although all Foxp3-expressing
cells from Foxp3DTR mice should express GFP. We observed that
the lack of Tregs, at tumor initiation, did not affect M2 infiltration
in IK tumors from SCID mice. However, at this stage, we cannot
exclude the possibility that depletion post-tumor development of
Figure 2. Foxp3 protein detected specifically in tumor-associated macrophages. (A and B) The spleen, the bone-marrow (BM) and the
kidney-tumor (IK tumor) have been harvested at day 14 from mice injected with Renca Ch+ L+ tumor cells intra-kidney. The same organs have been
harvested from naı¨ve non-injected mice. Representative flow cytometric analysis of Foxp3 expression are represented for T regulatory cells (TReg)
(stained with anti-TCRb, anti-CD4 and anti-CD25 antibodies), macrophages, other myeloid cells (both stained with anti-F4/80, anti-CD11b antibodies),
dendritic cells (DCs) (stained with CD11c antibocy) and B cells (stained with CD19 antibody) in (A) naı¨ve BALB/C mice and (B) Renca Ch+L+ IK tumor-
bearing BALB/C mice. Black line represents FJK-16S clone for anti-Foxp3 antibody and grey line a Rat IgG2A isotype control (eBioscience, clone
eBR2a). (C) Representative flow cytometric staining on TReg (stained with anti-TCRb, anti-CD4 and anti-CD25 antibodies) from naı¨ve spleen (left
panel) and myeloid cells (stained with CD11b antibody) from naı¨ve bone marrow (right panel) with FJK-16S anti-Foxp3 antibody (grey dashed line)
and two different clones for rat IgG2A isotype control: clone eBR2a from eBisocience (black line) and clone R35-95 from BD Bioscience (grey line).
doi:10.1371/journal.pone.0108670.g002
Foxp3 Expression in Macrophages
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TRegs that were present at tumor initiation was influencing the
macrophage profile in the tumor, potentially explaining the lower
level of M2 in IK tumors in Foxp3DTR mice. Furthermore, the
lower level of Foxp3 expression in macrophages compared to
TRegs that we observed, would involve a lower level of DTR-
eGFP protein in the cells. This could make GFP expression hard
to detect in macrophages and also explain a lower depletion of M2
cells compared to TRegs.
In addition to detection of Foxp3 at the protein level, we
demonstrated, using two sensitive molecular techniques, the
Figure 3. M2 from tumors in SCID mice express Foxp3 and are depleted in tumors in Foxp3DTR mice after DT injection. (A) Wild type
(WT) or SCID BALB/c mice were inoculated at day 0 with 26105 Renca Ch+ L+ tumor cells. Intra-kidney tumors were harvested at day 14 and processed
for flow cytometric analysis. Representative flow cytometric histogram and dot plots of Foxp3 expression in T regulatory cells (TRegs) (stained with
anti-TCRb, anti-CD4 and anti-CD25 antibodies) and type-2 (M2) macrophages (stained with anti-F4/80 and anti-CD11b antibodies) from IK tumors are
depicted. Black line represents anti-Foxp3 antibody and grey line a rat IgG2A isotype control. M2 percentage (in the F4/80hi/CD11bint gate) of total
macrophages is represented. (B) Western blot for Foxp3 protein on M2 sorted from the IK tumor at day 14 from WT and SCID BALB/C mice. FJK16S
antibody clone was used. (C and D) Foxp3DTR mice were injected at day 0 with 26105 Renca Ch+ L+ tumor cells and processed for flow cytometric
analysis. Representative flow cytometry and (E) quantitative data of percent of positive cells for Foxp3-eGFP expression in TRegs (C and upper
panel of E) and macrophages (D and lower panel of E) from IK tumors and blood 4 days after diphteria toxin injection (DT inj) or not (Ctl) are
depicted. Representative graph of gating strategy for (C) TRegs (Foxp3+/CD25+/CD4+/TCRb+) cells and (D) macrophages (F4/80+/CD11b+) or M2 (F4/
80hi/CD11bint) are shown. (C) Percentages represent TCRb+/CD4+ cells of all CD45.2+/CD4+ cells (first and fourth columns of C) and percent of CD4+/
CD25+ cells of all TCRb+/CD4+ cells (second and fifth columns of C); (1 representative experiment among 3, n = 4 mice per group). (D) Percentages
represent F4/80+/CD11b+ monocytes/macrophages in the blood (first column of D), or M2 cells in the IK tumors (third column of D) of all CD45.2+; (2
experiments pooled). ***P,0.0005, ****P,0.0001.
doi:10.1371/journal.pone.0108670.g003
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presence of Foxp3 mRNA in renal tumor infiltrating macrophag-
es. The Foxp3 transcript detected in the macrophages was
previously unknown and exhibited a shorter sequence than
previously known Foxp3 mRNA. At this stage, we do not rule
out that an alternate start codon within the new variant of Foxp3
mRNA could explain the extra weight of the macrophage Foxp3
protein. Interestingly, we detected low level of Foxp3 mRNA in
Renca tumor cells isolated from in vivo solid tumors but not from
in vitro tissue culture though we do not know yet which isoform it
was. Some reports in the literature suggest a potential oncogenic
and tumor escape function of Foxp3 in tumor cells [7,21].
However we didn’t detect any Foxp3 protein in those tumor cells,
suggesting that Foxp3 message detected using RT-PCR may have
been due to contaminating macrophages or TRegs present in the
in vivo tumor FACS-isolated sample.
Taken together, our results strongly suggest that Renca tumor-
associated macrophages, in particular those with a M2 profile,
express mRNA and a potentially post translationally-modified
protein for Foxp3. We also attempted some analyses using mass
spectrometry to confirm the status of Foxp3 protein in the
macrophages and its level of post-translational modification.
Unfortunately, none of three Foxp3-specific antibodies
(eBioscience, BD Bioscience and Abcam) that we used, were
effective for Foxp3 protein immunoprecipitation necessary for
Figure 4. Foxp3 mRNA was detected in macrophages. Mice were inoculated with 26105 Renca Ch+ L+ tumor cells at day 0 intra-kidney. At day
14, tumors were harvested, CD4 T cells, type-2 (M2) and type-1 macrophages were sorted by gating respectively on TCRb+/CD4+ for CD4+ cells, F4/
80hi/CD11bint for M2 and F4/80int/CD11bhi for M1. Total RNA was extracted and RNA-sequencing (RNAseq) was performed. (A) Graph of distribution
of the level of total transcripts detected per sample. The level is expressed as abundance of the transcripts and genes in FPKM units (Fragments Per
Kilobase of transcript per Million mapped reads). The x-axis is in log scale. The Min. Level (black line) corresponds to Mean – 26Standard Deviation.
The high confidence line (purple line) corresponds to the 10th percentile of all transcripts. FPKM levels .0.0044 means RNA is significantly present,
and .0.046 means they are significantly present with high confidence. (B) Table representing the level of Foxp3 mRNA variants (var) in FPKM value
identified in CD4+ T cells (positive control) and M2 and M1 macrophages sorted from IK Renca tumors. The values in grey are less than 0.0044 FPKM
and insignificant, the values in black are between 0.0044 and 0.046 FPKM and present with relatively low abundance and the values in dark red-bold
are above 0.046 FPKM and significantly present. All transcript variants have been aligned on NCBI BLAST with Mus musculus transcriptome. (C)
Schematic representation of the overlapping sequences of Foxp3 mRNA variants (var) 2, 3 and 4 with variant 1, identified in the RNAseq on M2, M1
and CD4+ T cells after analysis using NCBI BLAST. Numbers represent base pair (bp) all normalized on variant 1. Black dash lines represent some
potential extra sequences on 59UTR not conserved on variant 1. (D) Agarose gel from reverse transcription-polymerase chain reaction from M2
macrophages (M2) sorted from IK tumors, Renca Ch+L+ cells from in vitro-tissue culture (Renca vit.), Renca Ch+L+ tumor cells sorted from in vivo IK
tumors at day 14 (Renca viv.), macrophages sorted from naı¨ve BALB/c mice BM (BM N.) or day 14 IK-tumor-bearing mice bone marrow (BM T.), T
regulatory cells sorted from Foxp3DTR mice (Reg.) and water as negative control (H2O). Reaction was performed using Foxp3 or HPRT primers as
depicted. (E) Western blot for Foxp3 using FJK-16S clone on bone marrow (BM) sorted macrophages from IK-tumor bearing mice (T.) or naı¨ve mice
(N.), IK-tumor infiltrating M2 macrophages (M2) and Renca Ch+L+ tumor cells from in vitro tissue culture (vit.) or sorted on Cherry expression from in
vivo IK tumor (viv.). (F) FACS analysis for Foxp3 expression on Renca Ch+L+ tumor cells from in vitro tissue culture (left panel) or from in vivo SC tumor
(middle panel) and IK tumor (right panel) at day 14 gated on CD45.2negative viable cells. Light grey curves represent Foxp3 antibody staining and dark
grey curves represent IgG2A isotype control.
doi:10.1371/journal.pone.0108670.g004
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sample isolation for mass spectrometry analysis. Furthermore,
being unable to immunoprecipitate the Foxp3 protein, we were
also unable to probe for the ubiquitin or SUMO modifications on
Foxp3. Consequently, there remain some unanswered questions
regarding the exact nature of the Foxp3 protein detected in
macrophages, which seems heavier than the Foxp3 present in
TRegs. Finally, some functional and mechanistic insight needs to
be performed, to reveal whether macrophage-expressed Foxp3 has
immunosuppressive activity.
Notwithstanding the above considerations of the nature and
function of the protein, the main purpose of the present study was
to clearly determine if Foxp3 could be expressed in macrophages
under some circumstances. Using diverse analytical techniques
such as flow cytometry, Western blot, RT-PCR and RNAseq, we
confirmed that Foxp3 could be expressed in macrophages in the
tumor context. This raises the possibility that Foxp3 could be an
interesting candidate to target to improve therapies for tumors
containing M2 infiltrating macrophages.
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